concentration were evaluated for each urine sample. Results: After randomization, 40 patients completed the study. Two patients, one in group 2 and one in group 3 dropped out. Patients in group 1 (125 mg furosemide) had a mean age of 77 ± 17 years, 43% were male, 6 (43%) had heart failure with a preserved ejection fraction (HFpEF), and 64% were in New York Heart Association (NYHA) class IV; the mean age of patients in group 2 (250 mg furosemide) was 80 ± 8.1 years, 15% were male, 5 (38%) had HFpEF, and 84% were in NYHA class IV; and the mean age of patients in group 3 (500 mg furosemide) was 73 ± 12 years, 54% were male, 6 (46%) had HFpEF, and 69% were in NYHA class IV. HSS added to furosemide increased total urine output, sodium excretion, urinary osmolality, and furosemide urine delivery in all patients and at all time points. The percentage increase was 18,14, and 14% for urine INTRODUCTION Heart failure (HF) is characterized by progressive fluid accumulation and a gradually decreased response to diuretic therapy [1] . Although the overall impact of diuretic therapy on HF mortality remains unclear, diuretics remain a mainstay of HF therapy [2, 3] . However, chronic treatment with diuretics may result in a phenomenon called ''chronic braking'' which limits the diuretic response and deteriorates the clinical status.
When the sodium and water excretion rate plateaus are achieved before adequate fluid elimination, a condition known as diuretic resistance occurs [4] . Pharmacokinetic and pharmacodynamic alterations are thought to be responsible for diuretic resistance in patients with HF [5] . As a matter of fact, the chronic use of loop diuretics leads to a functional adaptation of the distal tubule that alters its ability for reabsorption and results in diuretic resistance [6] . Sodium reabsorption in the distal tubule increases significantly when loop diuretics augment sodium delivery to this segment.
Brater et al. [7] described the response to intravenous (IV) furosemide administration using a fit sigmoid-shaped curve in patients with HF and in healthy controls evidencing that in HF, the curve shifts down and to the right indicating reduced furosemide and sodium excretion into urine. Moreover, several studies in patients with chronic HF (CHF) have reported that IV infusion of hypertonic saline solution (HSS) plus high-dose furosemide is more effective than furosemide alone [8] [9] [10] [11] [12] , resulting in increased urine output. These findings have allowed for greater weight loss, a shorter length of hospitalization [13] [14] [15] [16] , a greater reduction in neurohormonal activation [17] , and a significant improvement in renal function [18] [19] [20] [21] .
To validate the promising effects of HSS administration, the primary endpoint of the present study was to investigate the behavior on the dose-response curve after IV administration of high doses of furosemide diluted in HSS in comparison with the same dose of furosemide diluted in normal saline in patients hospitalized with refractory CHF.
METHODS
Patients were suitable for recruitment if they had presented with acute decompensated HF in the previous 24 h; diagnosis was made on the basis of the manifestation of at least one symptom (dyspnea, orthopnea, or edema) and one sign (pulmonary rales, lower limb edema, ascites, or lung vascular congestion on chest radiography) of HF according to European Society of Cardiology Criteria [22] . Additional inclusion criteria were a history of CHF treated with oral loop diuretics, at a dose of between 125 mg and 500 mg daily of furosemide, for at least 1 month before hospitalization. There were no pre-specified inclusion criteria regarding left ventricular ejection fraction (LVEF An independent team of nurses prepared the solutions and had an independent physician follow the process. A complete physical examination, including body weight (BW), BP, and heart rate (HR), was performed in all selected patients after randomization. Serum Na, K, Cl, bicarbonate, albumin, uric acid, creatinine, blood urea nitrogen (BUN) and glucose were determined through venous blood samples before treatment. Just after IV bolus of furosemide, urine samples were collected and measured using an urinometer, according to the protocol described by Brater et al. [7] , at 30, 60, and 90 min, and at 3, 4, 5, 6, 8, and at 24 h (T1-T9) after normal saline and HSS. This was given in association with fluid intake restriction (1000 mL/day) and a dietary sodium intake of 2.8 g/day (120 mmol/day). Urine samples were consecutively numbered and signed by physicians blinded to the study protocol, and immediately frozen at -20°C. Samples were subsequently delivered to the Regional Quality Control Laboratory (RQCL) for the quantification of urinary furosemide, natriuresis, and osmolality and analyzed by an external blinded team of physicians. Urinary excretion of furosemide was assayed with HPLC-MS/MS (High-Performance Liquid Chromatography-tandem mass spectrometry) method [13] . Urine furosemide excretion data was processed by an external computer scientist, blinded to the study protocol, to obtain dose-response curves.
Echocardiographic Analysis
Echocardiograms using a GE Vivid TM for the analysis in LC-MS/MS or for the creation of urine samples fortified were obtained starting from stock solutions by dilution with water or methanol, using a dilution factor less than 10 in each step of dilution.
HPLC-MS/MS Analysis [24]
LC-MS/MS analyses were performed using an HPLC Accela 1000 (Thermo Fisher Scientific) equipped with a refrigerated autosampler, degasser, and thermostatic chamber for the column chromatographic, interfaced to a tandem-mass high-resolution spectrometer Q-Exactive (Thermo Fisher Scientific) coupled with atmospheric pressure heated source, H-ESI II. Chromatographic separation was obtained using a Thermo HyperSil Gold C18 PFP column (50 mm 9 2.1 mm i.d., 1.9 lm particle size), 
Data Analysis
Computer fitting to a sigmoid-shaped curve of furosemide excretion rate and response ''dose-response curves'' relationship was examined using the following formula:
where Y (response) is the urinary sodium excretion rate, X is the furosemide excretion rate, a is the lower asymptote (i.e., response when dose = 0), b is the ''slope factor'' that determines inclination of the curve; c is the dose representing half-maximal response 
RESULTS
After randomization, the three groups of patients who received one of the IV diuretic dosages were: fourteen patients who received Similar behavior was observed for total urinary osmolality ( Table 3 ). The link between furosemide release and natriuretic response is shown in Fig. 3 . 
DISCUSSION
The amount of drug reaching the renal tubule is the most important determinant of the response to a diuretic [26] . The drug can be quantified by the ratio of sodium excretion Values are presented as mean ± standard deviation. Normal saline (0.9%) and hypertonic Saline (1.4%). BUN blood urea nitrogen, HR heart rate SBP systolic blood pressure relative to urinary diuretic concentration [27] . Glomerular filtration rates are relatively normal in most patients with CHF but their renal blood flow is reduced [28] . Since furosemide gains access to its intraluminal site of action by active secretion at the proximal tubule, a decreased blood flow could limit delivery to the secretory site. Consequently, patients with CHF may not respond because of reduced delivery of diuretic to the site of action. The present study suggests that furosemide tubular delivery increases over time in all groups but a higher furosemide concentration is observed when HSS is added.
The relationship between excretion of sodium and urine furosemide delivery was represented as a curve encompassing the time course of the entire study, fitted as a sigmoid function. To explain these data, we assumed that the effect of the infusion of HSS has realized a dual action that would justify the observed variation of the exerts its positive effects in the kidney acting as a sort of ''bait'' for the action of the diuretic by facilitating its action with a twofold effect [29, 30] . Intuitively, these results are reliable with an increase in effective kidney blood volume that leads to an explanation for the quantitative and qualitative variations of urine.
Another explanation may consist in the functional attitude of the kidney that changes in response to a load of sodium and water. Deep nephrons, due to their well-developed loops of Henle, are more efficient in the reabsorption of water and sodium (salt-saving nephrons) while superficial nephrons due to their short developed loops of Henle are more efficient in the excretion of water and sodium (salt-losing nephrons) [31] . During increased loads of water and sodium occurring after administration of HSS, there is a change in the auto regulation of renal plasma flow, more marked in the cortex rather than in the renal medulla, and, as a consequence, blood flow is increased and the filtration rate in the superficial nephrons (salt-losing nephrons) is also increased [31] .
The present investigation shows that the beneficial effects of HSS evidenced in previous studies [8-12, 15, 16] are supported by the fact that HSS administered in conjunction with furosemide Table 3 Delta modification of total furosemide excretion, total sodium excretion, total diuresis and total urine osmolality in the study population Parameters 
